Results 81 to 90 of about 72,887 (326)

Comprehensive Review on PARP Inhibitors in Ovarian Cancer: A Breakthrough in Diagnostic and Therapeutic Approaches

healthbook TIMES. Oncology Hematology, 2023
Ovarian cancer, a challenging malignancy often diagnosed in advanced stages, has witnessed a transformative shift in treatment paradigms with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors. These agents that target DNA repair pathways
Marcus Vetter, Viola Heinzelmann
doaj   +1 more source

Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors [PDF]

, 2017
The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show that CRISPR-Cas9–mediated silencing of the HuR locus increases the relative sensitivity of PDAC
Brody, Jonathan R., Chand, Saswati N., Cozzitorto, Joseph A., Jiang, Wei, Knudsen, Karen E., Lal, Shruti, Londin, Eric R., Meisner-Kober, Nicole, Nevler, Avinoam, Pascal, John M, Pishvaian, Michael J., Romeo, Carmella, Sanan, Akshay R., Schiewer, M. J., Scolaro, Laura, Winter, Jordan M., Yeo, Charles, Zarei, Mahsa   +17 more
core   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

PARP inhibitors in castration-resistant prostate cancer

Cancer Treatment and Research Communications, 2020
Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA
Abhishek Tripathi, Pragathi Balakrishna, Neeraj Agarwal   +2 more
doaj   +1 more source

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. [PDF]

, 2015
Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were recently shown to have potential clinical impact in a number of disease settings, particularly as related to cancer therapy, treatment for cardiovascular dysfunction, and suppression of inflammation ...
de Bono, Johann S., Feng, Felix Y., Knudsen, Karen E, Rubin, Mark A.   +3 more
core   +2 more sources

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms [PDF]

Clinical Cancer Research, 2016
Abstract Purpose: DNA repair defects have been previously reported in myeloproliferative neoplasms (MPN). Inhibitors of PARP have shown activity in solid tumors with defects in homologous recombination (HR). This study was performed to assess MPN sensitivity to PARP inhibitors ex vivo. Experimental Design: HR pathway
Keith W, Pratz, Brian D, Koh, Anand G, Patel, Karen S, Flatten, Weijie, Poh, James G, Herman, Robert, Dilley, Maria I, Harrell, B Douglas, Smith, Judith E, Karp, Elizabeth M, Swisher, Michael A, McDevitt, Scott H, Kaufmann   +12 more
openaire   +2 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers [PDF]

, 2022
Yicong Bian, Jian Meng, Sheng Ma, Guangze Li, Yuya Wang, Shaorong Li, Linsheng Liu, Chenrong Huang, Hua Zhang, Dafang Zhong, Liyan Miao   +10 more
openalex   +1 more source

Poly(ADP-Ribose) Polymerase 1 Accelerates Single-Strand Break Repair in Concert with Poly(ADP-Ribose) Glycohydrolase [PDF]

, 2007
Single-strand breaks are the commonest lesions arising in cells, and defects in their repair are implicated in neurodegenerative disease. One of the earliest events during single-strand break repair (SSBR) is the rapid synthesis of poly(ADP-ribose) (PAR)
Caldecott, Keith W, Fisher, Anna E O, Hochegger, Helfrid, Takeda, Shunichi   +3 more
core   +2 more sources

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP‐ribose) glycohydrolase inhibitor

FEBS Open Bio, EarlyView.
We analyzed alterations of PAR metabolism‐related proteins in PARG inhibitor‐resistant HCT116RPDD cells. Although PARG levels remained unchanged, HCT116RPDD cells exhibited reduced PARP1 and ARH3 expression and elevated PAR levels. Interestingly, HCT116RPDD cells exhibited slightly elevated intracellular NAD+/NADH and ATP levels. Our findings suggest a
Kaede Tsuda, Yoko Ogino, Akira Sato
wiley   +1 more source